



WEEKLY EPIDEMIOLOGICAL REPORT

A publication of the Epidemiological Unit,

Ministry of Healthcare & Nutrition

231, de Saram Place, Colombo 01000, Sri Lanka.

Tele:(+94-011)2695112, 681548, 4740490, 4740492, 2677600 Fax: 2696583

Epidemiologist:(+94-011) 4740491, E-mail:chepid@slt.net.lk, epidunit@slt.net.lk

Web: www.epid.gov.lk

Vol. 35 No. 36

30th August– 5th September 2008

Meningococcal meningitis - Part II

Part I of this article was published in the last issue of the Weekly Epidemiological Report.

Clinical manifestations

A great obstacle in diagnosing meningococcal disease is that clinical manifestations are hard to tell apart from other, less serious upper respiratory tract infections. Acute purulent meningitis is the usual manifestation of meningococcal disease. It is believed that meningeal infection is the result of haematogenous dissemination of the bacterium. This is observed in 50% of patients and is similar in its initial manifestations to other types of bacterial meningitis. The symptoms start with sudden, fever, stiff neck, nausea, vomiting, photophobia, and neurological alterations that may include stupor, delirium, coma, and convulsions. In infants, meningitis may be more difficult to identify, with atypical symptoms of a stiff neck, but a swollen fontanel may be present. Also, the child may be irritable, cry inconsolably, vomit, have seizures, refuse to eat, and be hypotonic.

Blood cultures are positive in 75% of *Meningococcal meningitis* patients. Meningococemia is difficult to identify in isolated cases, as opposed to outbreaks. However, it is characterized by sudden fever, purpuric or petechial exanthema, which may progress to purpura or fulminant septicemia, associated with hypotension, acute adrenal hemorrhage (Waterhouse-Friderichsen syndrome) and multiple organ failure. Sometimes the exanthema associated with meningococcal

disease may be maculopapular, similar to a viral exanthema, non-pruritic and transient, lasting approximately two days. Serogroups A and C are most commonly associated with meningitis out-breaks. However, they can also be present as meningococemia.

N. meningitidis may affect the respiratory tract causing pneumonia, epiglottitis, and otitis media. Pneumonia occurs in 5 to 15% of invasive meningococcal disease cases, particularly when serogroups Y and W-135 are involved. Diagnosis of meningococcal pneumonia is difficult because isolation of the bacterium from sputum cannot differentiate asymptomatic carriers from diseased individuals. Some focal infections also occur in the form of septic arthritis, urethritis, pericarditis and conjunctivitis.

The latter type of infection may become complicated in 18% of cases, progressing from a localized infection of the conjunctiva to meningococemia or bacterial meningitis. Chronic meningococemia is rather uncommon and is characterized by intermittent fever, exanthema, arthralgia, and cephalgia.

Standard case definition of meningococcal meningitis and meningococemia

- *Suspected case of acute meningitis*: Sudden Onset of fever (>38.5°C rectal or 38°C axillary) with stiff neck. In patients under one year of age, a suspected case of meningitis occurs when fever is accompanied by a bulging fontanelle.
- *Probable case of bacterial meningitis*: Sus-

Contents

Page

1. Leading Article - Meningococcal meningitis - Part II	1
2. Surveillance of vaccine preventable diseases & AFP (23 rd – 29 th August 2008)	3
3. Summary of newly introduced notifiable diseases (23 rd – 29 th August 2008)	3
4. Laboratory surveillance of dengue fever (23 rd – 29 th August 2008)	3
5. Summary of selected notifiable diseases reported (23 rd – 29 th August 2008)	4

WEEKLY EPIDEMIOLOGICAL REPORT SRI LANKA 2008

epidemic, or petechial or purpurial rash.

- **Confirmed case:** Suspected or probable case as defined above, with either positive CSF antigen detection for *N. meningitidis*, or positive culture of CSF or blood with identification of *N. meningitidis*

This case definition allows the detection of cases of meningococcal septicaemia

Diagnosis

Diagnosis of meningococcal meningitis is based upon analysis of cerebrospinal fluid. The adequate medium is Mueller-Hinton or GC enriched with supplement, which have replaced agar chocolate medium. Gram stain of the cerebrospinal fluid is an important test for prompt and accurate identification of *N. meningitidis*. Commercial kits are available to detect the polysaccharide antigen in cerebrospinal fluid and are also very useful for preliminary diagnosis of meningococcal disease, including sero-group identification. False negative results may occur, particularly when serogroup B is involved. Currently, testing is performed with the polymerase chain reaction (PCR) in cerebrospinal samples, to identify the sero-group, with the advantage of not requiring live organisms to perform the test with a sensitivity and specificity greater than 90%.

In addition to cerebrospinal fluid abnormalities, one may find high white cell counts with an increased number of polymorphonuclear cells. When severe purpura occurs, it is usually associated with systemic intravascular coagulation. Blood cultures are frequently positive. When purpuric lesions occur, direct microscopic observation and culture of tissue specimens or pus may provide the diagnosis.

Differential diagnosis of meningococcal disease mainly has to exclude other bacterial meningitis caused by *Streptococcus pneumoniae* and *Haemophilus influenzae*. Meningococemia is hard to tell apart from other acute febrile illnesses, particularly in the absence of purpuric exanthema. However, the presence of fever, purpura, and shock strongly suggests a diagnosis of meningococcal disease.

Treatment

At the beginning of the 20th century, mortality from meningococcal disease was 70%. The introduction of IV fluid therapy and sulfas caused a reduction in the case-fatality rates of this disease. However, even with the use of adequate supportive care and antibiotics, case fatality rates of between 9 and 12% have remained stable in the past 20 years. The case fatality rate of meningococemia is high. The patient must be admitted to a hospital

or clinic for diagnosis and treatment. Infectivity of patients is moderate and fades away soon after antimicrobial therapy; thus, isolation of the patient is not considered necessary after the initial 24-48 h. Antibiotics, include penicillin G, beta lactamic derivatives, ampicillin sulbactam combinations, amoxicillin, clavulanic acid, and cephalosporines like cefotaxime, ceftriaxone, cefuroxime and cefepime .

Third generation cephalosporines like ceftriaxone and cefotaxime are excellent but costly alternatives. Nevertheless, ceftriaxone frequently becomes the ideal alternative, since it can be administered once a day for periods as short as two days. The high morbidity and mortality rates associated with meningococcal disease, even in patients who are given appropriate antimicrobial therapy, suggest that some anti-inflammatory therapies may help to improve clinical prognosis. It has been estimated that 11 to 19% of meningococcal disease survivors are left with sequel like deafness, neurological abnormalities, and loss of a limb in cases of meningococemia. Some studies have suggested that routine utilization of corticosteroids like dexamethasone may be useful prior to antimicrobial therapy to diminish meningeal inflammation caused by bacterial death; however, its use has not been established as standard therapy. Traditionally, two clinical situations are acknowledged to require the use of steroids to prevent sequel and probably to improve sur-

Macroscopic characteristics: murky or purulent.	
WBC count:	>1000 cells/mm ³ with over 80% polymorphonuclears.
Proteins:	>80 g/L
Glucose:	<0.4 g/L
Gram stain:	Gram negative intracellular diplococci in 80% of untreated cases.

vival of patients; one is neurological damage resulting from meningeal inflammation identified at the moment of diagnosis, the other is the presence of a Gram stain positive for *N. meningitidis* .

Treatment is recommended for seven days in most countries. Intensive care by properly trained personnel is recommended for patients with severe disease, septic shock, fulminant purpura, meningitis, and coma.

CSF Characteristics in Meningococcal meningitis

Sources

1. *Meningococcal meningitis* : WHO Fact sheet N°141
2. A. Sachdeva, S. Kukreja, V. Jain and A.K. Dutta . Meningococcal Disease - Outbreak in Delhi. Indian Pediatrics 2005; 42:547-556.
3. Control of Communicable Diseases Manual by David

23rd - 29th August 2008 (35th Week)

Table 1: Vaccine-preventable Diseases & AFP

Disease	No. of Cases by Province									Number of cases during current week in 2008	Number of cases during same week in 2007	Total number of cases to date in 2008	Total number of cases to date in 2007	Difference between the number of cases to date between 2008 & 2007
	W	C	S	N	E	NW	NC	U	Sab					
Acute Flaccid Paralysis	01 CO=1	01 NE=1	00	00	00	00	01 AP=1	00	00	03	00	70	59	+18.6%
Diphtheria	00	00	00	00	00	00	00	00	00	00	00	00	00	00.0%
Measles	00	01 NE=1	02 HB=2	00	00	01 KR=1	00	00	00	04	00	89	50	+78.0%
Tetanus	01 GM=1	01 KD=1	00	00	00	00	00	00	00	02	02	27	26	+3.8%
Whooping Cough	01 GM=1	01 NE=1	00	00	00	00	00	00	00	02	00	32	31	+3.2%
Tuberculosis	29	125	04	13	03	00	23	00	08	206	80	6204	6704	-7.5%

Table 2: Newly Introduced Notifiable Diseases

23rd - 29th August 2008 (35th Week)

Disease	No. of Cases by Province									Number of cases during current week in 2008	Number of cases during same week in 2007	Total number of cases to date in 2008	Total number of cases to date in 2007	Difference between the number of cases to date between 2008 & 2007
	W	C	S	N	E	NW	NC	U	Sab					
Chicken-pox	12	02	03	00	01	09	02	08	06	43	46	3693	2315	+59.5%
Meningitis	04 GM=1 KL=1 CB=2	02 KD=3	00	01 JF=1	00	04 KR=4	03 AP=2 PO=1	01 BD=1	0 KG=1 RP=1	17	23	941	375	+150.9%
Mumps	04	10	08	00	02	15	01	09	13	62	36	1991	1238	+60.8%

Key to Table 1 & 2

Provinces: W=Western, C=Central, S=Southern, N=North, E= East, NC=North Central, NW=North Western, U=Uva, Sab=Sabaragamuwa.

DPDHS Divisions: CB=Colombo, GM=Gampaha, KL=Kalutara, KD=Kandy, ML=Matale, NE=Nuwara Eliya, GL=Galle, HB=Hambantota, MT=Matara, JF=Jaffna, KN=Killinochchi, MN=Mannar, VA=Vavuniya, MU=Mullaitivu, BT=Batticaloa, AM=Ampara, TR=Trincomalee, KM=Kalmunai, KR=Kurunegala, PU=Puttalam, AP=Anuradhapura, PO=Polonnaruwa, BD=Badulla, MO=Moneragala, RP=Ratnapura, KG=Kegalle.

Table 3: Laboratory Surveillance of Dengue Fever

23rd - 29th August 2008 (35th Week)

Samples	Number tested		Number positive *		Serotypes										
					D ₁		D ₂		D ₃		D ₄		Negative		
	GT	AH	GT	AH	GT	AH	GT	AH	GT	AH	GT	AH	GT	AH	
Number for current week	02	02	00	00	00	00	00	00	00	00	00	00	00	00	00
Total number to date in 2008	126	132	09	22	00	00	06	08	01	08	00	00	02	00	

Sources: Genetech Molecular Diagnostics & School of Gene Technology, Colombo [GT] and Genetic Laboratory Asiri Surgical Hospital [AH]

* Not all positives are subjected to serotyping.

NA= Not Available.

Data Sources:

Weekly Return of Communicable Diseases: Diphtheria, Measles, Tetanus, Whooping Cough, Human Rabies, Dengue Haemorrhagic Fever, Japanese Encephalitis, Chickenpox, Meningitis, Mumps.

Special Surveillance: Acute Flaccid Paralysis.

National Control Program for Tuberculosis and Chest Diseases: Tuberculosis.

**Table 4: Selected notifiable diseases reported by Medical Officers of Health
23rd - 29th August 2008 (35th Week)**

DPDHS Division	Dengue Fever / DHF*		Dysentery		Encephalitis		Enteric Fever		Food Poisoning		Leptospirosis		Typhus Fever		Viral Hepatitis		Human-Rabies		Returns Receive %
	A	B	A	B	A	B	A	B	A	B	A	B	A	B	A	B	A	B	
Colombo	21	1232	11	164	00	11	10	84	02	78	43	349	00	02	01	90	00	00	92
Gampaha	19	755	00	144	00	16	00	39	00	96	59	397	00	06	05	107	00	04	86
Kalutara	07	362	04	242	00	11	00	45	01	19	14	359	00	02	00	33	01	02	100
Kandy	08	196	03	224	01	06	01	46	00	54	01	325	02	81	02	98	00	01	72
Matale	01	87	00	156	00	02	00	36	00	04	00	614	00	01	00	24	00	00	83
Nuwara Eliya	00	22	07	193	00	02	00	198	00	166	00	39	00	35	01	90	00	01	77
Galle	01	85	01	137	00	12	01	14	00	43	06	252	00	12	00	06	00	03	53
Hambantota	01	74	02	71	00	05	00	07	00	11	02	76	00	71	01	14	01	01	91
Matara	03	224	02	141	00	11	00	29	00	06	17	275	09	164	02	14	00	01	88
Jaffna	00	52	01	103	02	04	00	223	02	13	00	00	00	151	01	33	00	00	63
Kilinochchi	00	00	00	26	00	00	00	01	00	04	00	02	00	00	00	01	00	00	00
Mannar	00	25	02	17	00	06	01	146	00	00	00	00	00	01	00	13	00	00	50
Vavuniya	00	11	03	49	00	02	02	10	01	15	00	05	00	01	00	05	00	00	75
Mullaitivu	00	00	00	09	00	00	00	13	00	13	00	00	00	01	00	09	00	00	00
Batticaloa	00	85	00	93	00	04	00	20	00	20	00	05	00	01	00	83	00	05	73
Ampara	00	28	01	227	00	00	00	07	00	01	00	20	00	00	00	08	00	00	57
Trincomalee	00	176	01	73	00	00	00	13	00	12	01	30	00	16	00	12	00	00	80
Kurunegala	01	267	04	175	00	14	02	49	02	16	43	389	01	24	01	55	00	04	89
Puttalam	01	272	02	65	00	08	00	137	00	26	01	36	00	33	00	28	00	03	78
Anuradhapur	00	111	02	66	00	09	00	10	00	06	00	223	00	10	00	13	00	02	58
Polonnaruwa	00	59	03	97	00	01	00	21	00	12	00	55	00	01	00	18	00	00	71
Badulla	02	71	08	357	00	05	05	110	00	93	04	43	00	100	05	113	00	01	87
Monaragala	02	51	02	283	00	03	00	33	00	116	00	87	03	81	01	39	00	00	82
Ratnapura	06	225	03	248	00	27	00	42	00	62	01	130	00	75	00	46	00	00	69
Kegalle	05	326	01	235	00	24	00	52	02	06	10	266	00	56	01	438	00	01	91
Kalmunai	00	33	05	215	00	02	00	09	00	16	01	01	00	02	00	21	00	00	46
SRI LANKA	78	4829	68	3810	03	185	22	1394	10	908	203	3978	15	927	21	1411	02	29	74

Source: Weekly Returns of Communicable Diseases (WRCD).

*Dengue Fever / DHF refers to Dengue Fever / Dengue Haemorrhagic Fever.

**Timely refers to returns received on or before 6 September, 2008 Total number of reporting units =238. Number of reporting units data provided for the current week: 227

PRINTING OF THIS PUBLICATION IS FUNDED BY THE UNITED NATIONS CHILDREN'S FUND (UNICEF).

Comments and contributions for publication in the WER Sri Lanka are welcome. However, the editor reserves the right to accept or reject items for publication. All correspondence should be mailed to The Editor, WER Sri Lanka, Epidemiological Unit, P.O. Box 1567, Colombo or sent by E-mail to chepid@sltnet.lk.

ON STATE SERVICE

Dr. M. R. N. ABEYSINGHE
 EPIDEMIOLOGIST
 EPIDEMIOLOGICAL UNIT
 231, DE SARAM PLACE
 COLOMBO 10